Showing 3881-3890 of 6035 results for "".
- Omeros: Omidria Demonstrates Benefits Across Traditional and Femtosecond Laser-Assisted Cataract Surgery and in IFIS Caseshttps://modernod.com/news/omeros-omidria-demonstrates-benefits-across-traditional-and-femtosecond-laser-assisted-cataract-surgery-and-in-ifis-cases/2480226/Omeros announced that the results of four real-world clinical studies evaluating the benefits of Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual
- Nine Members of Congress Honored for Efforts to Preserve Access to Quality Medical Eye Carehttps://modernod.com/news/nine-members-of-congress-honored-for-efforts-to-preserve-access-to-quality-medical-eye-care/2480228/The American Academy of Ophthalmology is honoring nine members of Congress whose legislative efforts are helping to preserve patient access to quality medical and surgical eye care. The Academy is presenting its 2018 Visionary Awards to Sen. Tom Carper, D-Del., Sen. Lisa Murkowski, R-Alaska, Sen.
- Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatanhttps://modernod.com/news/aerie-pharmaceuticals-announces-appointment-of-scott-laranjo-as-director-marketing-roclatan/2480254/Aerie Pharmaceuticals announced the appointment of Scott Laranjo as Director, Marketing, Roclatan, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Laranjo will direct future marketing activities associated with Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005
- Market Scope: Patient Demand for Better Vision Will Drive Double-Digit Growth in IOL Revenueshttps://modernod.com/news/patient-demand-for-better-vision-will-drive-double-digit-growth-in-iol-revenues/2480268/Technological innovations in premium IOLs will help drive global IOL revenues to more than $6.1 billion by 2023, according to Market Scope data.
- Zeiss Expands Ophthalmic Workflow Portfolio in Canada with Diagnostic, Visualization, and Therapeutic Solutionshttps://modernod.com/news/zeiss-expands-ophthalmic-workflow-portfolio-in-canada-with-diagnostic-visualization-and-therapeutic-solutions/2486373/Key Takeaways Zeiss introduced a broader portfolio of diagnostic devices, therapeutic lasers, and digital workflow tools to enhance eye care deliv
- WCO, Alcon Launch Dry Eye Management Map for Optometrists Worldwidehttps://modernod.com/news/wco-alcon-launch-dry-eye-management-map-for-optometrists-worldwide/2486349/The World Council of Optometry (WCO) and Alcon have launched the Dry Eye Management Map, a new online interactive tool designed to help optometrists evaluate and manage dry eye disease in cl
- Vital Tears and Brightstar Therapeutics Form Joint Medical Advisory Boardhttps://modernod.com/news/vital-tears-and-brightstar-therapeutics-form-joint-medical-advisory-board/2486040/Vital Tears and Brightstar Therapeutics have announced the formation of a joint Medical Advisory Board, bringing together nine leaders in ophthalmology and optometry to help guide the organizations’ expanding clinical and scientific initiatives.
- Edinburgh Biosciences Showcases Light-Based Cataract Treatment Platform at 100% Optical 2026https://modernod.com/news/edinburgh-biosciences-showcases-light-based-cataract-treatment-platform-at-100-optical-2026/2486017/At the 100% Optical 2026 meeting, Edinburgh Biosciences introduced the SDS-100, the company’s proprietary system designed to deliver its Photon Protein Modulation (PPM) treatment. The exhibition provided the first opportunity f
- Zeiss Launches Collaborative Care Platform to Enhance Connected Ophthalmic Carehttps://modernod.com/news/zeiss-launches-collaborative-care-platform-to-enhance-connected-ophthalmic-care/2485780/Key Takeaways Zeiss Collaborative Care is designed to enables ECPs to
- FDA Officially Shifts to One-Trial Standard for New Drug Approvalshttps://modernod.com/news/fda-officially-shifts-to-one-trial-standard-for-new-drug-approvals/2485753/The FDA has announced a major change to its regulatory framework, formally establishing that a single well-designed pivotal clinical trial will be the new default basis for most drug and therapeutic approvals—replacing the long-standing expectation that two indepen